ARCHIVES

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

This article is from The Cancer Letter archive.

Vol. 17 No. 31 | August 2, 1991

Download PDF Visit The Full Archive

Related Articles

FDA Moves to Regulate Lab-Developed Tests

August 1, 2014

NCI Advisors Criticize Plan To Fund R01s On ESA Research With Amgen, J&J Money.

June 27, 2008

Lenalidomide Maintenance Increased PFS and Survival

May 25, 2012

Unscreened Women At High Risk of Breast Cancer

October 29, 2004

Assurances On Methods For Misconduct Reporting Required

December 1, 1989

AIDS Biological Specimens Available From NIH

November 22, 1985